Analyzing Eagle Pharmaceuticals (EGRX) & The Competition

Eagle Pharmaceuticals (NASDAQ: EGRX) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Eagle Pharmaceuticals to similar businesses based on the strength of its analyst recommendations, dividends, risk, institutional ownership, earnings, profitability and valuation.

Insider and Institutional Ownership

66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 19.5% of Eagle Pharmaceuticals shares are held by insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Eagle Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals’ competitors have a beta of 0.85, suggesting that their average share price is 15% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Eagle Pharmaceuticals and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eagle Pharmaceuticals 1 0 3 0 2.50
Eagle Pharmaceuticals Competitors 63 299 947 27 2.70

Eagle Pharmaceuticals currently has a consensus price target of $72.50, indicating a potential upside of 35.64%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 17.52%. Given Eagle Pharmaceuticals’ higher possible upside, analysts clearly believe Eagle Pharmaceuticals is more favorable than its competitors.

Profitability

This table compares Eagle Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eagle Pharmaceuticals 39.32% 66.30% 48.44%
Eagle Pharmaceuticals Competitors -538.85% -41.85% -24.81%

Valuation and Earnings

This table compares Eagle Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Eagle Pharmaceuticals $245.88 million $83.99 million 8.98
Eagle Pharmaceuticals Competitors $2.40 billion $905.93 million 1.01

Eagle Pharmaceuticals’ competitors have higher revenue and earnings than Eagle Pharmaceuticals. Eagle Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Eagle Pharmaceuticals beats its competitors on 8 of the 13 factors compared.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

What are top analysts saying about Eagle Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eagle Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit